Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.

Trial details

Who runs it

Immunovant Sciences GmbH

Trial code

EU 2024-512646-42-00

Record updated

2025. október 8.

Original description

Period 2/ Cohort A: To evaluate the efficacy of batoclimab compared to placebo in maintaining clinical response as assessed by adjusted inflammatory neuropathy cause and treatment (Adj INCAT) score in participants receiving immune globulin (IVIg or SCIg) or plasma exchange (PLEX) treatment for CIDP at the time of screening.Read full original descriptionShow less

A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Period 2/ Cohort A: To evaluate the efficacy of batoclimab compared to placebo in maintaining clinical response as assessed by adjusted inflammatory neuropathy cause and treatment (Adj INCAT) score in participants receiving immune globulin (IVIg or SCIg) or plasma exchange (PLEX) treatment for CIDP at the time of screening.

Inclusion: Are >= 18 years at the Screening Visit; Have met clinical diagnostic criteria for typical CIDP, or one of the following CIDP variants: multifocal CIDP, focal CIDP, or motor CIDP in accordance with the EAN/PNS Guideline on the Diagnosis and Treatment of CIDP. Clinical criteria for typical CIDP and variants are as follows (either criteria must be met): a. Typical CIDP: All the following: - Progressive or relapsing, symmetric, proximal, and distal muscle weakness of upper and lower limbs, and sensory involvement of at least two limbs (at any point in the disease course) - Developing over at least 8 weeks - Absent or reduced tendon reflexes in all limbs b. CIDP variants: One of the following, but otherwise as in typical CIDP (tendon reflexes may be normal in unaffected limbs): - Multifocal CIDP: documented sensory loss and muscle weakness in a multifocal pattern, usually asymmetric, upper limb predominant - Focal CIDP: sensory loss and muscle weakness in only one limb - Motor CIDP: motor symptoms and signs without sensory involvement; Cohorts A and B - Have electrodiagnostic test results supporting the diagnosis of CIDP in accordance with the EAN/PNS Guideline on the Diagnosis and Treatment of CIDP (either criteria must be met): a. Motor nerve conduction criteria strongly supportive of demyelination. b. Motor nerve conduction criteria weakly supportive of demyelination and 2 or more of the following additional diagnostic criteria: - Objective improvement to an empiric trial of therapy with immunoglobulin treatment, plasma exchange (PLEX) or corticosteroids. - Diagnostic imaging by ultrasound or magnetic resonance imaging (MRI) supporting the diagnosis of CIDP by demonstrating nerve enlargement. - Cerebrospinal fluid (CSF) demonstrating albuminocytologic dissociation (i.e., elevated CSF protein level [defined as > 70 milligrams per deciliter {mg/dL} or more than 10 mg/dL greater than years of age for those aged 60 years and over] with normal CSF white blood cell [WBC] level). - Nerve biopsy demonstrating features supporting the diagnosis of CIDP such as edema, demyelination, and/or onion bulb formation; Cohort C only: Have a diagnosis of CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP based on clinical criteria and motor nerve conduction criteria strongly supportive of demyelination (i.e., motor nerve conduction criteria weakly supportive of demyelination is insufficient diagnostic evidence for admission to Cohort C); Cohort D only: Have met only clinical diagnostic criteria for typical CIDP, or one of the following CIDP variants: multifocal CIDP, focal CIDP, or motor CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP. Either inclusion criterion 2(a) or 2(b) must be met; Additional inclusion criteria are defined in the protocol.

Exclusion: Have current or prior history of immunoglobulin M (IgM) paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies; Are receiving chronic oral corticosteroids monotherapy at a dose > 40 mg/day prednisolone/prednisone or its equivalent at the Screening Visit; Are receiving chronic oral corticosteroid at a dose > 10 mg/day prednisolone/prednisone or equivalent in combination with immunoglobulin therapy or PLEX at the Screening Visit; Have polyneuropathy of causes other than CIDP including but not limited to: a. Multifocal motor neuropathy b. Hereditary demyelinating neuropathy c. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes (i.e., POEMS) d. Lumbosacral radiculoplexus neuropathy e. Systemic illnesses including vitamin deficiency syndromes and paraneoplastic neuropathies f. Drug- or toxin-induced; Have diabetes mellitus (DM) and meets any of the following criteria: a. Does not meet inclusion criteria 2(a) and 3(a) b. In the opinion of the Investigator, there is evidence of poorly controlled DM preceding the diagnosis of CIDP. c. In the opinion of the Investigator, there is evidence of poorly controlled DM at screening; Have a history of myelopathy or evidence of central demyelination; Have Distal CIDP, Sensory CIDP or are suspected of having a diagnosis of auto-immune nodopathy in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP; Additional exclusion criteria are defined in the protocol.

EU CTIS 2024-512646-42-00